GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Marinus Pharmaceuticals
Marathon Oil is a large independent oil and gas company. Its stock price directly tracks oil and gas prices. The chart reflects its operating performance in US shale fields.
Share prices of companies in the market segment - Neuro
Marinus Pharmaceuticals is a pharmaceutical company developing drugs to treat rare epileptic and seizure disorders. We've categorized it as a "Neurology" company. The chart below reflects how investors assess the risks and prospects in this complex area of medicine.
Broad Market Index - GURU.Markets
Marinus Pharmaceuticals is a pharmaceutical company specializing in the development of drugs for the treatment of rare epileptic seizures. As a significant player, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with Marinus's performance to assess the state of the sector.
Change in the price of a company, segment, and market as a whole per day
MRNS - Daily change in the company's share price Marinus Pharmaceuticals
Marinus Pharmaceuticals, Inc.'s daily share price fluctuations reflect the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its epilepsy drugs.
Daily change in the price of a set of shares in a market segment - Neuro
Marinus Pharmaceuticals develops drugs to treat rare epileptic seizures. Neuroscience is a risky field of research. The chart below illustrates the high volatility typical of the biotech sector, reflecting the stakes associated with Marinus Pharmaceuticals' development.
Daily change in the price of a broad market stock, index - GURU.Markets
Marinus Pharmaceuticals is a biotech company specializing in the treatment of central nervous system diseases. Its shares are driven by news of clinical trials. This high volatility is a significant component of the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Marinus Pharmaceuticals
Marinus Pharmaceuticals' year-over-year performance is a story of the commercialization of its drug for the treatment of rare forms of epilepsy. Its market capitalization growth over the past 12 months reflects sales of Ztalmy® and, more importantly, progress in developing its intravenous formulation for the treatment of status epilepticus, which could significantly expand its market.
Annual dynamics of market capitalization of the market segment - Neuro
Marinus, a late-stage biotech company, develops drugs for the treatment of neurological diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Marinus Pharmaceuticals, a company developing drugs to treat rare forms of epilepsy, is a niche player in the neurosciences industry. Its annual market capitalization is determined by FDA decisions and the commercial success of its flagship product, making it unaffected by general economic cycles.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Marinus Pharmaceuticals
Marinus is a commercial biopharmaceutical company focused on neurological diseases. Its monthly performance is driven by sales of its drug Ztalmy and progress in clinical trials for new indications.
Monthly dynamics of market capitalization of the market segment - Neuro
This chart reflects the dynamics of the biotech sector, particularly in neuroscience. For Marinus, a commercial company, it's the backdrop. Its movements show how the successful launch of its drug and progress in clinical trials impact its valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Marinus Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of rare forms of epilepsy. Its value is determined by the commercial success of its approved drug and the results of new studies. The overall market chart provides only background, while Marinus's performance is determined by clinical news and sales reports.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Marinus Pharmaceuticals
The weekly performance of Marinus, a biopharmaceutical company focused on epilepsy treatment, reflects the company's ongoing search for new therapeutic options. Share prices are reacting sharply to clinical trial data and the commercial success of its drugs for treating rare forms of seizures.
Weekly dynamics of market capitalization of the market segment - Neuro
Marinus Pharmaceuticals develops drugs to treat rare epileptic seizures. The chart helps separate its own news-driven dynamics from the broader fluctuations in the neuroscience sector, showing how the market views its chances of success in this complex field.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Marinus Pharmaceuticals develops drugs for the treatment of neurological diseases. Shares of such innovative biotech companies often move independently of the market. This chart will help you understand: is Marinus living in its own world of clinical trials, or is the overall market environment influencing its stock price?
Market capitalization of the company, segment and market as a whole
MRNS - Market capitalization of the company Marinus Pharmaceuticals
Marinus's market capitalization is a story about developing drugs to treat rare epileptic seizures. Its volatile chart is a trajectory of clinical trials and FDA decisions. Its dynamics are a narrative of hope for patients and binary risks for investors, where the success or failure of one drug determines everything.
MRNS - Share of the company's market capitalization Marinus Pharmaceuticals within the market segment - Neuro
Marinus Pharmaceuticals specializes in treating rare neurological diseases. Its share of the biotech sector's market capitalization is directly dependent on the success of clinical trials. The chart below illustrates investor confidence in the company's drugs' potential to become a new standard of treatment and capture the market.
Market capitalization of the market segment - Neuro
Marinus Pharmaceuticals is a company developing drugs to treat rare forms of epilepsy and other neurological disorders. The chart below shows the market capitalization of this complex sector. Its dynamics reflect the enormous need for new treatments and the high risks associated with their development.
Market capitalization of all companies included in a broad market index - GURU.Markets
Marinus Pharmaceuticals develops drugs to treat rare epileptic seizures. Its market cap represents hope for patients and their families. Its volatile performance on the overall chart reflects how clinical trial successes and failures impact the fortunes of biotech companies.
Book value capitalization of the company, segment and market as a whole
MRNS - Book value capitalization of the company Marinus Pharmaceuticals
Marinus Pharmaceuticals' foundation is its capital invested in the development and commercialization of drugs for the treatment of rare forms of epilepsy. This is a real, scientific foundation aimed at helping patients with severe seizure disorders. How has this neurological biotech asset evolved? The chart below shows its dynamics.
MRNS - Share of the company's book capitalization Marinus Pharmaceuticals within the market segment - Neuro
Marinus Pharmaceuticals develops drugs to treat rare forms of epilepsy, which requires R&D laboratories. The chart shows the share of these science-intensive tangible assets, reflecting the physical foundation of its fight against neurological diseases.
Market segment balance sheet capitalization - Neuro
Marinus, a biopharmaceutical company, has a moderately capital-intensive business. This requires ownership of R&D and control over the production of its drugs. The BCap_Seg chart for the biotech sector shows that commercial success requires a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
Marinus Pharmaceuticals' book value is derived from its intellectual property, which covers drugs for treating rare forms of epilepsy. The company's assets are the capitalized results of years of research. The chart below shows how this neuroscience-focused biotech compares in terms of asset size.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Marinus Pharmaceuticals
Marinus Pharmaceuticals develops drugs to treat neurological disorders. Its book value represents R&D costs. Its market capitalization represents the company's hopes for approval and commercial success. The chart reflects investor expectations at each stage of clinical trials, which are fraught with risk and potential breakthroughs.
Market to book capitalization ratio in a market segment - Neuro
Marinus Pharmaceuticals develops and commercializes drugs for the treatment of rare, difficult-to-treat forms of epilepsy. Its market valuation is heavily dependent on the success of clinical trials and the commercial potential of its lead product, making it a typical representative of the volatile biotech sector.
Market to book capitalization ratio for the market as a whole
Marinus Pharmaceuticals focuses on developing treatments for neurological disorders. The company's core assets are its patents and clinical trial results. Its market valuation reflects investor expectations for success. This chart helps assess how far expectations in the biotech sector are ahead of the market.
Debts of the company, segment and market as a whole
MRNS - Company debts Marinus Pharmaceuticals
Marinus Pharmaceuticals, a company developing drugs to treat rare forms of epilepsy, uses capital to commercialize its approved product and conduct further clinical trials. This chart shows how the company is funding its transition from R&D to full-fledged commercialization, which requires significant marketing and sales expenditures.
Market segment debts - Neuro
Marinus Pharmaceuticals is a commercial pharmaceutical company specializing in the treatment of rare epilepsy disorders. The approval of a product changes the financial picture, but R&D continues. This chart shows how the company balances sales revenue with expenses for further clinical research while managing its debt.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Marinus Pharmaceuticals
Marinus Pharmaceuticals specializes in drugs for the treatment of rare neurological disorders, particularly epilepsy. Developing such drugs requires significant investment. This chart shows the company's reliance on debt to finance its clinical trials, a key indicator of its financial risk.
Market segment debt to market segment book capitalization - Neuro
Marinus Pharmaceuticals specializes in developing drugs to treat rare epilepsy disorders. Neuroscience is a complex and capital-intensive field. The chart shows how aggressively the biotech sector uses debt for R&D, providing context for how Marinus finances its clinical programs.
Debt to book value of all companies in the market
Marinus Pharmaceuticals, focused on treating rare epilepsy disorders, requires significant investment in clinical trials. This chart, showing the market's overall debt burden, helps assess financial risks. It helps understand how the company's R&D capital raising strategy aligns with the high standards and risks of the biotech sector.
P/E of the company, segment and market as a whole
P/E - Marinus Pharmaceuticals
Marinus Pharmaceuticals develops drugs to treat rare epilepsy disorders. This chart shows how the market views its focus on this complex disease. The company's valuation is heavily dependent on the success of its key drug in clinical trials, regulatory approval, and commercial launch.
P/E of the market segment - Neuro
This chart shows the average valuation for biopharmaceutical companies, providing context for Marinus Pharmaceuticals. It reflects overall sentiment in the sector. Comparisons with these values help understand how the market views Marinus's focus on developing drugs for rare epilepsy disorders, especially after receiving approval for its first product.
P/E of the market as a whole
Marinus Pharmaceuticals is a biopharmaceutical company specializing in developing drugs for the treatment of rare epilepsy disorders. Its valuation depends entirely on the success of its drugs in clinical trials and regulatory approval. Overall market sentiment, reflected in this chart, is completely irrelevant to the company.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Marinus Pharmaceuticals
This chart for Marinus Pharmaceuticals, which specializes in treating rare epilepsy disorders, shows market expectations for sales of its flagship drug. It reflects analysts' forecasts for patient growth and the successful launch of new indications, which informs future profitability estimates.
%20P%2FE%20Marinus%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Marinus-Pharmaceuticals&v=1772513915859 "Chart of the company's future (projected) P/E Marinus Pharmaceuticals")
Future (projected) P/E of the market segment - Neuro
Marinus Pharmaceuticals specializes in developing drugs for the treatment of rare epileptic disorders, specifically using ganaxolone. The company's future depends on the success of clinical trials. The chart shows forecasts for the pharmaceutical industry, allowing us to assess how market expectations for Marinus differ from general trends in neurology.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Neuro&v=1772513915861 "Future (projected) P/E graph of the market segment - Neuro")
Future (projected) P/E of the market as a whole
Marinus Pharmaceuticals, Inc. develops drugs to treat rare epileptic seizures. The company's valuation is heavily dependent on the success of its clinical programs and regulatory approvals. This overall market sentiment profile impacts the company's ability to raise capital to bring life-saving drugs to market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513915875 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Marinus Pharmaceuticals
Marinus Pharmaceuticals develops drugs to treat rare epilepsy disorders. The company already has an approved product and continues research. This chart shows the transition from a loss-making R&D company to a commercial organization, reflecting both sales revenue and ongoing research expenses.
Profit of companies in the market segment - Neuro
Marinus Pharmaceuticals specializes in developing drugs to treat rare epileptic seizures. This chart, reflecting profitability in the neuroscience sector, demonstrates the importance of finding solutions for severe CNS diseases. Their focus on rare forms of epilepsy allows them to carve out a unique niche and bring hope to patients with limited treatment options.
Overall market profit
Marinus Pharmaceuticals specializes in developing drugs to treat rare epileptic seizures. The company's success depends on regulatory approval and commercialization of its lead product. This overall market return chart reflects the investment climate that allows biotech companies like Marinus to fund their expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Marinus Pharmaceuticals
Marinus Pharmaceuticals specializes in developing drugs to treat rare epileptic seizures and other neurological disorders. Its future depends on the approval and commercial success of its lead product. This chart displays analyst consensus estimates for future sales, which are key to valuing a biotech company.
%20profit%20of%20the%20company%20Marinus%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Marinus-Pharmaceuticals&v=1772513916104 "Graph of future (projected) profit of the company Marinus Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Neuro
Marinus Pharmaceuticals is a pharmaceutical company specializing in the development of drugs for the treatment of rare epilepsy disorders. Its main product addresses significant unmet medical needs. This biotech chart reflects the general expectations for companies operating in the orphan (rare) disease niche, where the commercial potential is very high.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Neuro&v=1772513916129 "Graph of future (predicted) profits of companies in a market segment - Neuro")
Future (predicted) profit of the market as a whole
Marinus Pharmaceuticals develops drugs for the treatment of rare epileptic disorders. Its primary driver is successful clinical trials. However, the overall economic situation reflected in this forecast affects the investment climate in the biotech sector and the valuation of similar companies.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513916158 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Marinus Pharmaceuticals
Marinus Pharmaceuticals develops drugs to treat rare epilepsy disorders. For a company launching its first product, this chart is crucial. It shows how investors assess the drug's sales potential, weighing the size of the target market and its commercial prospects in neurology.
P/S market segment - Neuro
Marinus Pharmaceuticals specializes in developing drugs for the treatment of rare and severe forms of epilepsy. The company's revenue depends on the successful commercialization of its key product and the development of clinical programs. This chart, which reflects the average valuation in the sector, helps understand how the market views Marinus's potential in neurological diseases.
P/S of the market as a whole
Marinus Pharmaceuticals is a company focused on developing drugs to treat rare epileptic seizures and other neurological disorders. This chart, which reflects market revenue estimates, serves as a measure of hope for Marinus. It shows how much investors value the company's potential to help patients for whom existing treatments are ineffective.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Marinus Pharmaceuticals
Marinus Pharmaceuticals is a pharmaceutical company focused on developing treatments for rare epilepsy disorders. Its future depends on the success of its key drug, Ztalmy. This chart reflects investor expectations for future sales growth for this drug and success in developing new indications for its use.
%20P%2FS%20Marinus%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Marinus-Pharmaceuticals&v=1772513916259 "The graph of the company's future (projected) P/S Marinus Pharmaceuticals")
Future (projected) P/S of the market segment - Neuro
Marinus Pharmaceuticals is a pharmaceutical company specializing in the development of drugs for the treatment of rare epilepsy disorders and other neurological diseases. This chart shows the average estimated future sales in the neurology sector. It helps understand how highly the market perceives the potential of Marinus's drugs for patients with serious illnesses.
%20P%2FS%20market%20segment%20graph%20-%20Neuro&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Neuro&v=1772513916261 "Future (projected) P/S market segment graph - Neuro")
Future (projected) P/S of the market as a whole
Marinus Pharmaceuticals specializes in developing drugs to treat rare and severe forms of epilepsy and other neurological disorders. This chart reflects the market's overall revenue expectations. The company's success in developing new treatments for patients unresponsive to existing medications contributes to the overall optimism of investors in the biotech sector.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513916272 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Marinus Pharmaceuticals
This chart shows the revenue of Marinus Pharmaceuticals, a company specializing in the treatment of rare epilepsy disorders. Its revenue is generated from sales of Ztalmy. The dynamics of this chart directly reflect the success of the commercial launch, the rate of adoption by physicians, and the patient reach.
Sales of companies in the market segment - Neuro
Marinus Pharmaceuticals specializes in developing drugs for the treatment of rare epileptic seizures. This graph illustrates the growth of the CNS drug market. The successful commercialization of Marinus's products not only changes the lives of patients with severe forms of epilepsy but also demonstrates the potential of new mechanisms of action, stimulating further research in this area.
Overall market sales
Marinus Pharmaceuticals develops drugs to treat rare epilepsy disorders. The company's success depends on regulatory approval and commercialization of its products. The overall economic situation, shown in this chart, impacts healthcare system funding and its ability to pay for innovative drugs.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Marinus Pharmaceuticals
Marinus Pharmaceuticals specializes in the treatment of rare epileptic seizures. The company's future revenue depends on successful sales of its approved drug and the development of its clinical pipeline. This chart shows analyst consensus estimates for the commercial potential of its drugs.
%20sales%20of%20the%20company%20Marinus%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Marinus-Pharmaceuticals&v=1772513916345 "Schedule of future (projected) sales of the company Marinus Pharmaceuticals")
Future (projected) sales of companies in the market segment - Neuro
Marinus Pharmaceuticals specializes in developing drugs for the treatment of rare and severe forms of epilepsy and other seizure disorders, particularly using neurosteroids. This chart shows the forecast for the entire neurological drug market, where there is a huge need for new, more effective epilepsy treatments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Neuro&v=1772513916385 "Schedule of future (projected) sales of companies in the market segment - Neuro")
Future (projected) sales of the market as a whole
Marinus Pharmaceuticals is a pharmaceutical company specializing in the development of treatments for rare epileptic seizures. The company's success depends on regulatory approval and the commercial launch of its drugs. This schedule, reflecting the overall economic situation, influences the pricing and availability of drugs for orphan diseases.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513916387 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Marinus Pharmaceuticals
Marinus Pharmaceuticals develops and markets drugs for the treatment of rare and severe forms of epilepsy. As the company transitions from the purely research to the commercial stage, it faces new challenges. This chart shows its path to profitability, which depends on successful product launch and the balance between sales revenue and ongoing research costs.
Market segment marginality - Neuro
Marinus Pharmaceuticals specializes in developing drugs for the treatment of rare and severe forms of epilepsy. With an approved product, the company's profitability depends on its successful commercialization and progress in clinical trials. This chart shows the financial results of their efforts to bring life-saving drugs to market for patients with neurological disorders.
Market marginality as a whole
Marinus Pharmaceuticals is a company focused on developing drugs to treat rare epileptic seizures and other neurological disorders. Their key product targets a specific mechanism in the brain. This overall profitability curve is irrelevant to them. Demand for their drugs is determined by the severity of the disease, not the state of the economy.
Employees in the company, segment and market as a whole
Number of employees in the company Marinus Pharmaceuticals
Marinus Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare neurological diseases. As its product enters the market, its team is expanding with sales personnel. This chart shows its transformation from a purely research-based company to a fully-fledged sales organization.
Share of the company's employees Marinus Pharmaceuticals within the market segment - Neuro
Marinus Pharmaceuticals specializes in developing drugs to treat rare epileptic seizures and other neurological disorders. This chart reflects the company's human capital profile within its pharmaceutical niche. The dynamics of this indicator are directly related to the intensity of clinical trials and the size of the scientific team working on the development of life-saving drugs.
Number of employees in the market segment - Neuro
Marinus Pharmaceuticals, Inc. is a pharmaceutical company specializing in the development of treatments for rare epileptic seizures. This chart reflects employment trends in the highly specialized field of neurology. The growth in the number of clinicians and regulatory affairs specialists here is directly related to progress in clinical trials and the company's move toward commercialization of its core product.
Number of employees in the market as a whole
Marinus Pharmaceuticals develops drugs to treat rare neurological diseases. The company's success depends on research results and patient access to treatment. Stable employment, as shown in this graph, provides more people with insurance coverage, improving access to expensive innovative drugs once they are approved.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Marinus Pharmaceuticals (MRNS)
Marinus Pharmaceuticals is a company focused on treating rare neurological diseases, particularly epilepsy. Its core business is scientific research and clinical trials. This chart shows that the company's market valuation is based on the potential of its drugs in development. Each employee is a scientist or physician, and the high market capitalization per employee reflects the value of their intellectual labor and future patents.
%20of%20the%20company%20Marinus%20Pharmaceuticals%20(MRNS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Marinus-Pharmaceuticals-MRNS&v=1772513916537 "Chart of market capitalization per employee (in thousands of dollars) of the company Marinus Pharmaceuticals (MRNS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Neuro
Marinus Pharmaceuticals is a biopharmaceutical company focused on developing drugs for the treatment of rare epilepsy disorders. Its value is determined by the potential of its clinical programs. This chart demonstrates the high market valuation of its research assets and prospects based on its small team of scientists.
%20by%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Neuro&v=1772513916569 "Market capitalization per employee (in thousands of dollars) by market segment - Neuro")
Market capitalization per employee (in thousands of dollars) for the overall market
Marinus Pharmaceuticals specializes in developing drugs to treat rare epileptic seizures. The chart illustrates its valuation in the niche field of neuroscience. The high market capitalization per employee reflects the significant potential of its drugs for patients with limited treatment options and the investors' faith in the research team.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513916605 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Marinus Pharmaceuticals (MRNS)
Marinus Pharmaceuticals is a pharmaceutical company that successfully launched Ztalmy, a drug for the treatment of a rare form of epilepsy. This represents a transition from R&D to commercialization. This chart illustrates this balance: profit per employee is the result of how Ztalmy sales revenue generated by a small sales team is related to the costs of the rest of the R&D team.
%20Chart%20Marinus%20Pharmaceuticals%20(MRNS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Marinus-Pharmaceuticals-MRNS&v=1772513916629 "Company Profit Per Employee (in thousands of dollars) Chart Marinus Pharmaceuticals (MRNS)")
Profit per employee (in thousands of dollars) in the market segment - Neuro
Marinus Pharmaceuticals is the company whose drug Ztalmy is approved for the treatment of a rare type of epilepsy. This figure reflects a challenging stage: the company is already generating revenue from its first product, but is simultaneously incurring significant R&D expenditures to expand its use and develop other drugs.
%20in%20the%20market%20segment%20-%20Neuro&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Neuro&v=1772513916636 "Chart of profit per employee (in thousands of dollars) in the market segment - Neuro")
Profit per employee (in thousands of dollars) for the market as a whole
Marinus Pharmaceuticals is a biopharmaceutical company specializing in the treatment of rare epileptic seizures. They have an approved drug (Ztalmy). This chart is intended to show the transition from R&D losses to profitability. It reflects how successfully the company's commercial team is bringing this niche drug to market.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513916655 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Marinus Pharmaceuticals (MRNS)
Marinus Pharmaceuticals develops drugs to treat rare epilepsy disorders. This chart reflects the commercial potential of its key product. Following approval and launch, growth in this indicator will demonstrate successful market entry and the effectiveness of its small team working with neurologists.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Marinus-Pharmaceuticals-MRNS&v=1772513916673 "Sales chart per company employee Marinus Pharmaceuticals (MRNS)")
Sales per employee in the market segment - Neuro
Marinus Pharmaceuticals is a company focused on treating rare epileptic seizures and already has an approved drug, Ztalmy. This chart shows how productive their commercial and scientific teams are. It measures drug sales revenue per employee, allowing one to assess their effectiveness in bringing a niche drug to market.
Sales per employee for the market as a whole
Marinus Pharmaceuticals specializes in the treatment of rare epilepsy disorders. The company is in the commercialization phase of its first approved drug, Ztalmy (for CDKL5). This graph is critical: it shows how effectively the company's small commercial team is starting to generate sales revenue while covering the costs of ongoing R&D.
Short shares by company, segment and market as a whole
Shares shorted by company Marinus Pharmaceuticals (MRNS)
Marinus Pharmaceuticals is a pharmaceutical company specializing in the treatment of rare epileptic seizures. It has one approved drug, Ztalmy. This chart shows bearish bets. Investors may doubt Ztalmy's commercial success or, more likely, bet on its lead candidate failing in clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Marinus-Pharmaceuticals-MRNS&v=1772513916755 "Short Shares Chart for the Company Marinus Pharmaceuticals (MRNS)")
Shares shorted by market segment - Neuro
Marinus Pharmaceuticals focuses on developing treatments for rare neurological diseases, particularly epilepsy. This is a risky biotech segment, where much depends on the success of clinical trials. This chart shows the total volume of short positions across the entire neurological biotech industry. It measures the level of market skepticism: whether investors believe the sector will face research setbacks or tightened regulations.
Shares shorted by the overall market
Marinus Pharma (MRNS) is a clinical-stage biotech company. Its survival depends entirely on access to capital markets. When this market pessimism indicator rises, it signals a "venture winter." Investors panic and flee unprofitable biotechs, fearing MRNS will be unable to raise capital.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Marinus Pharmaceuticals (MRNS)
This chart for Marinus is a binary bet on epilepsy treatment. The company successfully launched Ztalmy (for a rare syndrome). "Overheating" (above 70) is driven by positive data in a new, larger indication—refractory status epilepticus. A failure in this key trial would send the stock plummeting (below 30).
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Marinus-Pharmaceuticals-MRNS&v=1772513916806 "RSI 14 indicator chart for the company's stock Marinus Pharmaceuticals (MRNS)")
RSI 14 Market Segment - Neuro
Marinus (MRNS) is a biotech company focused on treating rare, catastrophic forms of epilepsy in children and adults. This chart measures the "manic-depressive" pulse of the entire Neuroscience sector. It shows when the entire industry is overheated by expectations of a breakthrough or oversold by news of yet another failure.
RSI 14 for the overall market
For Marinus Pharma, a biotech company, this graph is a lifeline. Its survival depends on funding R&D. During periods of market euphoria, investors are willing to generously fund risky but promising research. During periods of panic, the money supply is turned off, and cash-burning companies risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast MRNS (Marinus Pharmaceuticals)
Marinus Pharmaceuticals is a biotech company focused on treating rare epileptic seizures. Its key drug, Ztalmy (Ganaxolone), is approved for the treatment of CDKL5. This chart shows the average 12-month price target from analysts, based on their sales growth forecasts for Ztalmy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-MRNS-Marinus-Pharmaceuticals&v=1772513916848 "A chart showing analyst consensus forecasts for the expected stock price. MRNS (Marinus Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price MRNS (Marinus Pharmaceuticals)
Marinus (MRNS) is a biotech company focused on treating rare forms of epilepsy (CDKL5 syndrome) with its drug Ztalmy. This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in commercialization and expansion of the R&D portfolio.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-MRNS-Marinus-Pharmaceuticals&v=1772513916849 "A chart showing the difference between the consensus forecast and the actual stock price. MRNS (Marinus Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Neuro
Marinus Pharma (MRNS) is a biotech company focused on treating rare (and severe) seizure disorders. Its flagship product (Ztalmy) is approved for a rare genetic epilepsy. This chart reflects the collective opinion of the *entire* neuroscience pharmaceutical sector. It shows whether experts believe in the commercial success of new epilepsy drugs.
Analysts' consensus forecast for the overall market share price
Marinus Pharma is a biotech company specializing in developing drugs for the treatment of rare neurological diseases, particularly epilepsy. This chart shows the overall market "risk appetite." For MRNS, a clinical-stage company, overall market optimism (as shown by the rising chart) is critical for raising capital for R&D.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Marinus Pharmaceuticals
Marinus is a biotech R&D company focused on the brain (CNS). Their signature product is the R&D of a drug (Ganaxolone), which they are seeking FDA approval for the treatment of a rare, severe form of epilepsy (status epilepticus). This chart is a pure R&D barometer of faith/fear. It reflects not sales, but the market's speculative valuation of their (very risky) pipeline and clinical data.
AKIMA Market Segment Index - Neuro
Marinus Pharmaceuticals is a neurobiotech focused on epilepsy. Their drug (based on neurosteroids) is aimed at treating rare, treatment-resistant forms of seizures. This chart compares their composite index to the sector, showing how their anticonvulsant R&D strategy compares to others.
The AKIM Index for the overall market
Marinus Pharmaceuticals is a biopharmaceutical company developing ganaxolone for the treatment of rare genetic epilepsies (CDKL5 syndrome). This chart, reflecting the market average, provides a macro backdrop. It helps assess how this neuroscience commercial story compares to overall economic trends.
